( Nasdaq : CGPI ) . leading topical drug for the treatment of inflammatory lesions of rosacea. development for the treatment of erythema associated with rosacea. receive $ 16.60 per share in cash. systemic product for the treatment of inflammatory lesions of rosacea. treatment of mild to moderate psoriasis. http : / / www.collagenex.com , which does not form part of this press release .